| Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19 MJ Levin, A Ustianowski, S De Wit, O Launay, M Avila, A Templeton, ... New England Journal of Medicine 386 (23), 2188-2200, 2022 | 604 | 2022 |
| MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a … P Ambery, VE Parker, M Stumvoll, MG Posch, T Heise, L Plum-Moerschel, ... The Lancet 391 (10140), 2607-2618, 2018 | 285 | 2018 |
| Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial MN Kosiborod, R Esterline, RHM Furtado, J Oscarsson, SB Gasparyan, ... The lancet Diabetes & endocrinology 9 (9), 586-594, 2021 | 196 | 2021 |
| Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study R Nahra, T Wang, KM Gadde, J Oscarsson, M Stumvoll, L Jermutus, ... Diabetes care 44 (6), 1433-1442, 2021 | 179 | 2021 |
| A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic … JLC Borges, JP Bilezikian, AR Jones‐Leone, AP Acusta, PD Ambery, ... Diabetes, Obesity and Metabolism 13 (11), 1036-1046, 2011 | 99 | 2011 |
| Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis M Fisher, MC Petrie, PD Ambery, J Donaldson, J Ye, JJV McMurray The Lancet Diabetes & Endocrinology 3 (9), 697-703, 2015 | 89 | 2015 |
| Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist VER Parker, D Robertson, T Wang, DC Hornigold, M Petrone, AT Cooper, ... The Journal of Clinical Endocrinology & Metabolism 105 (3), 803-820, 2020 | 86 | 2020 |
| Efficacy and safety of low‐dose otelixizumab anti‐CD 3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized, placebo … P Ambery, TW Donner, N Biswas, J Donaldson, J Parkin, CM Dayan Diabetic medicine 31 (4), 399-402, 2014 | 84 | 2014 |
| Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes NM Edner, F Heuts, N Thomas, CJ Wang, L Petersone, R Kenefeck, ... Nature immunology 21 (10), 1244-1255, 2020 | 70 | 2020 |
| A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus EA McKie, JL Reid, PC Mistry, SL DeWall, L Abberley, PD Ambery, ... PloS one 11 (3), e0150018, 2016 | 68 | 2016 |
| MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, phase 1 study PD Ambery, S Klammt, MG Posch, M Petrone, W Pu, C Rondinone, ... British journal of clinical pharmacology 84 (10), 2325-2335, 2018 | 63 | 2018 |
| Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the … M Kosiborod, O Berwanger, GG Koch, F Martinez, O Mukhtar, S Verma, ... Diabetes, Obesity and Metabolism 23 (4), 886-896, 2021 | 61 | 2021 |
| Specific associations of insulin resistance with impaired health-related quality of life in the Hertfordshire Cohort Study W Schlotz, P Ambery, HE Syddall, SR Crozier, AA Sayer, C Cooper, ... Quality of Life Research 16, 429-436, 2007 | 59 | 2007 |
| 40th EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5–9 September 2004 M Veitenhansl, K Stegner, FX Hierl, C Dieterle, H Feldmeier, B Gutt, ... Diabetologia 47, A1-A464, 2004 | 51 | 2004 |
| Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status CJ Currie, ER Berni, TR Berni, S Jenkins-Jones, M Sinsakul, L Jermutus, ... PLoS One 14 (8), e0221044, 2019 | 49 | 2019 |
| LB5. PROVENT: phase 3 study of efficacy and safety of AZD7442 (Tixagevimab/Cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults MJ Levin, A Ustianowski, S De Wit, O Launay, M Avila, S Seegobin, ... Open forum infectious diseases 8 (Supplement_1), S810-S810, 2021 | 36 | 2021 |
| Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic … VER Parker, T Hoang, H Schlichthaar, FW Gibb, B Wenzel, MG Posch, ... Diabetes, Obesity and Metabolism 24 (7), 1360-1369, 2022 | 34 | 2022 |
| Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy PD Home, B Ahrén, JEB Reusch, M Rendell, PN Weissman, DT Cirkel, ... Diabetes Research and Clinical Practice 131, 49-60, 2017 | 27 | 2017 |
| Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese … M Asano, A Sekikawa, H Kim, RA Gasser Jr, D Robertson, M Petrone, ... Diabetes, Obesity and Metabolism 23 (8), 1859-1867, 2021 | 24 | 2021 |
| Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19 GR Abraham, RE Kuc, M Althage, PJ Greasley, P Ambery, JJ Maguire, ... Journal of Molecular and Cellular Cardiology 167, 92-96, 2022 | 22 | 2022 |
